A Study of Mosunetuzumab in People With Follicular Lymphoma
The purpose of this study is to find out if mosunetuzumab is an effective treatment in people with follicular lymphoma that was recently diagnosed and have not yet received any treatments for their disease.
Follicular Lymphoma|Lymphoma
DRUG: Mosunetuzumab|DRUG: Zanubrutinib
Rate of Complete Respons/CR, The primary objective of the study is to determine the rate of Complete Response/CR to single-agent SC mosunetuzumab according to the 2014 Lugano response criteria in participants with newly diagnosed Follicular Lymphoma in need of systemic therapy., Up to 1 year
Overall Response Rate/ORR, Assess the Overall Response Rate/ORR after treatment with single-agent SC mosunetuzumab mosunetuzumab, Up to 3 years
After completing enrollment of the initial 53 subjects, the researchers plan to expand the study by an additional 23 subjects.